What is Wedbush's Forecast for NBIX Q2 Earnings?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Investment analysts at Wedbush lowered their Q2 2025 EPS estimates for Neurocrine Biosciences in a research note issued on Tuesday, July 15th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of $1.00 for the quarter, down from their prior forecast of $1.12. Wedbush has a "Outperform" rating on the stock. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share. Wedbush also issued estimates for Neurocrine Biosciences' Q3 2025 earnings at $1.30 EPS and FY2027 earnings at $8.97 EPS.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). The business had revenue of $572.60 million for the quarter, compared to analyst estimates of $587.06 million. Neurocrine Biosciences had a net margin of 12.68% and a return on equity of 11.81%. The firm's quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.20 earnings per share.

A number of other research analysts have also recently issued reports on the stock. Canaccord Genuity Group lifted their price objective on shares of Neurocrine Biosciences from $158.00 to $160.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. JPMorgan Chase & Co. raised their price target on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the company an "overweight" rating in a research report on Wednesday, March 26th. Piper Sandler reissued an "overweight" rating and set a $154.00 price target (down from $160.00) on shares of Neurocrine Biosciences in a research report on Tuesday, May 6th. Guggenheim raised their price target on shares of Neurocrine Biosciences from $155.00 to $165.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Finally, Evercore ISI dropped their price target on shares of Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Three analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the stock. According to data from MarketBeat.com, Neurocrine Biosciences currently has an average rating of "Moderate Buy" and a consensus target price of $163.91.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX traded up $0.63 during mid-day trading on Thursday, reaching $134.11. 674,476 shares of the company's stock traded hands, compared to its average volume of 1,146,525. The stock has a market cap of $13.27 billion, a P/E ratio of 45.46, a PEG ratio of 1.37 and a beta of 0.24. The business has a 50-day simple moving average of $125.18 and a 200 day simple moving average of $121.53. Neurocrine Biosciences has a 1-year low of $84.23 and a 1-year high of $157.98.

Insider Activity

In other Neurocrine Biosciences news, Director William H. Rastetter sold 30,000 shares of the stock in a transaction on Monday, May 5th. The shares were sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the completion of the sale, the director owned 37,491 shares of the company's stock, valued at $4,131,508.20. This represents a 44.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Jude Onyia sold 59,819 shares of the company's stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $130.46, for a total transaction of $7,803,986.74. Following the completion of the transaction, the insider owned 18,289 shares of the company's stock, valued at $2,385,982.94. This trade represents a 76.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 120,251 shares of company stock worth $14,978,602. 4.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Neurocrine Biosciences

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Neurocrine Biosciences by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 10,119,641 shares of the company's stock worth $1,381,331,000 after buying an additional 122,681 shares during the last quarter. Dodge & Cox boosted its holdings in shares of Neurocrine Biosciences by 83.5% in the first quarter. Dodge & Cox now owns 5,534,624 shares of the company's stock worth $612,129,000 after buying an additional 2,518,199 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Neurocrine Biosciences by 44.0% in the first quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company's stock worth $232,037,000 after buying an additional 640,556 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Neurocrine Biosciences by 2.9% in the fourth quarter. AQR Capital Management LLC now owns 1,896,891 shares of the company's stock worth $258,926,000 after buying an additional 53,610 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Neurocrine Biosciences by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 1,875,062 shares of the company's stock worth $255,523,000 after acquiring an additional 15,830 shares during the period. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.